Hostname: page-component-848d4c4894-ttngx Total loading time: 0 Render date: 2024-05-25T00:14:31.628Z Has data issue: false hasContentIssue false
  • English
  • Français

Immunogenicity of yeast-derived hepatitis B vaccine from two different producers

Published online by Cambridge University Press:  15 May 2009

E. Dahl-Hansen ,
J. Chr. Siebke ,
S. S. Frøland  and
M. Degré
E. Dahl-Hansen
Affiliation:
Department of Internal Medicine and Institute of Bacteriology, The National Hospital of Norway, 0027 Oslo 1 and Department of Virology, National Institute of Public Health, 0462 Oslo 4, Norway
J. Chr. Siebke
Affiliation:
Department of Internal Medicine and Institute of Bacteriology, The National Hospital of Norway, 0027 Oslo 1 and Department of Virology, National Institute of Public Health, 0462 Oslo 4, Norway
S. S. Frøland
Affiliation:
Department of Internal Medicine and Institute of Bacteriology, The National Hospital of Norway, 0027 Oslo 1 and Department of Virology, National Institute of Public Health, 0462 Oslo 4, Norway
M. Degré*
Affiliation:
Department of Internal Medicine and Institute of Bacteriology, The National Hospital of Norway, 0027 Oslo 1 and Department of Virology, National Institute of Public Health, 0462 Oslo 4, Norway
*
*Prof. M. Degré, Institute of Bacteriology, Rikshospitalet, 0027 Oslo, Norway.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The immunogenicity and reactogenicity of two preparations of yeast-derived hepatitis B vaccinces were compared in healthy adult populations. The two groups were vaccinated in parallel, but they were not matched for age and sex. All subjects seroconverted, and 9 months after the first vaccine dose, all had anti HBs titres of at least 10 IU/1. The anti-HBs titres were higher in the group of subjects given 20μg vaccine antigen made by Smith Kline & RIT (GMT 2943 at 9 months) compared to those who received 10μg of vaccine made by Merck, S harp & Dohme (GMT 729 at 9 months). Adverse effects were recorded in 32·0 and 44·7% of the participants, but these were limited to minor local and general reactions. In the present study both preparations were safe and efficient.

Type
Research Article
Information
Epidemiology & Infection , Volume 104 , Issue 1 , February 1990 , pp. 143 - 149
Copyright
Copyright © Cambridge University Press 1990

References

REFERENCES

1.Szmuness, W, Stevens, CE, Zang, EA, Harley, EJKellner, A.A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981; 1: 377–85.CrossRefGoogle ScholarPubMed
2.Valenzuella, P, Medina, A, Rutter, WJ, Ammerer, GHall, BD.Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298: 347–50.CrossRefGoogle Scholar
3.Harford, N, Cabezon, T, Crabeel, M, et al. , Expression of hepatitis B surface antigen in yeast. Develop Biol Stand 1983 54: 125–30.Google ScholarPubMed
4.Jilg, W, Schmidt, M, Zoulek, G, Lorbeer, B, Wilske, B, Deinhardt, F.Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 1984; ii: 1174–5.CrossRefGoogle Scholar
5.Davidson, M, Krugman, S.Immunogenicity of recombinant yeast hepatitis B vaccine. Lancet 1985; i: 108–9.CrossRefGoogle Scholar
6.Bergamini, F, Zanetti, A.Immunogenicity of yeast–derived hepatitis B vaccines in young adults. Postgrad Med J 1987; 63 (Suppl. 2): 137–8.Google ScholarPubMed
7.Goudeau, A, Denis, F, Mounier, M, et al. , Comparative multi–centre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers. Postgrad Med J 1987; 63 (Suppl. 2): 125–8.Google Scholar
8.Odaka, N, Eldred, L, Cohn, S, et al. , Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. JAMA 1988; 260: 3635–7.CrossRefGoogle ScholarPubMed
9.Milne, A, Brawner, TA, Dumbill, PC, Kawachi, I, Pearce, NEComparison of the immunogenicity of reduced doses of two recombinant Dna hepatitis B vaccines in New Zealand children.J Med Virol 1989; 27: 264–7.CrossRefGoogle ScholarPubMed
10.Frisch-Niggemeyer, W, Ambrosch, FHofman, H.The assessment of immunity against hepatitis B after vaccination. J Biol Stand 1986; 14: 255–8.CrossRefGoogle ScholarPubMed
11.Goudeau, A, Coursaget, P, Barin, F, et al. , Prevention of hepatitis B by active and passive– active immunization. In: Szmuness, W, Alter, HJ, Maynard, JE. eds. Viral hepatitis. Philadelphia: The Franklin Institute Press, 1982: 509–25.Google Scholar
12.Ambrosch, F.Frisch-Niggemeyer, P, Kremsner, P, et al. , Persistence of vaccine–induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgrad Med J 1987; 63 (Suppl. 2): 129–35.Google ScholarPubMed
13.Hadler, SC.Francis, DP, Maynard, JE, et al. , Long term immunogenicity, and efficacy of hepatitis B vaccine in homosexual men. New Engl J Med 1986; 315: 209–14.CrossRefGoogle ScholarPubMed
14.Holinger, FB, Hepatitis B vaccines – to switch or not to switch? JAMA 1987; 257: 2634–6.CrossRefGoogle Scholar
15.Walgate, R.Hepatitis, B.Taiwan plans mass vaccination. Nature 1984; 312: 190.CrossRefGoogle ScholarPubMed